Johnson & Johnson (NYSE:JNJ) Shares Purchased by Delaney Dennis R

Delaney Dennis R grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 40,032 shares of the company’s stock after acquiring an additional 730 shares during the period. Johnson & Johnson comprises about 3.0% of Delaney Dennis R’s investment portfolio, making the stock its 15th biggest holding. Delaney Dennis R’s holdings in Johnson & Johnson were worth $5,789,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of JNJ. Gabelli Funds LLC increased its holdings in Johnson & Johnson by 1.3% in the fourth quarter. Gabelli Funds LLC now owns 195,485 shares of the company’s stock valued at $28,271,000 after buying an additional 2,450 shares during the last quarter. Jump Financial LLC increased its holdings in shares of Johnson & Johnson by 2,001.9% in the 4th quarter. Jump Financial LLC now owns 31,717 shares of the company’s stock valued at $4,587,000 after acquiring an additional 30,208 shares during the last quarter. Anchor Investment Management LLC raised its position in shares of Johnson & Johnson by 0.8% during the 4th quarter. Anchor Investment Management LLC now owns 91,625 shares of the company’s stock valued at $13,251,000 after acquiring an additional 752 shares in the last quarter. M Holdings Securities Inc. bought a new position in Johnson & Johnson during the fourth quarter worth $2,451,000. Finally, Lafayette Investments Inc. increased its stake in Johnson & Johnson by 1.2% during the fourth quarter. Lafayette Investments Inc. now owns 48,960 shares of the company’s stock valued at $7,081,000 after purchasing an additional 597 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 1.5 %

Shares of JNJ stock opened at $154.08 on Tuesday. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The business’s fifty day moving average is $159.38 and its 200-day moving average is $155.11. The stock has a market cap of $371.31 billion, a PE ratio of 23.17, a price-to-earnings-growth ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the business earned $2.29 earnings per share. Johnson & Johnson’s revenue for the quarter was up 5.3% compared to the same quarter last year. Equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on JNJ shares. Raymond James reduced their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a research report on Monday. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Leerink Partners lowered their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $163.00 to $164.00 and gave the company an “equal weight” rating in a report on Wednesday, April 9th. Eight research analysts have rated the stock with a hold rating, nine have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $171.50.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.